Tarter Krinsky & Drogin’s client NanoViricides, Inc. (OTCBB:  NNVC.OB), recently raised $5 million, drawing down on its shelf registration statement. NanoViricides sold 500,000 shares of its Series B Convertible Preferred Stock to a single investor at a price of $10 per share.

NanoViricides is a development-stage biopharmaceutical company that is creating special-purpose nanomaterials for viral therapy. The company’s novel nanoviricide® class of drug candidates are designed to attack and dismantle virus particles. 

Peter Campitiello, a Partner in TKD’s Corporate and Securities Practice Group, represented NanoViricides in the transaction.